Gilead Sciences, Inc. | Large-cap | Healthcare
$108.50
0.46%
| Gilead Sciences Stock Comparison:
Gilead Sciences vs Eli Lilly andGilead Sciences vs Johnson & JohnsonGilead Sciences vs Merck & CoGilead Sciences vs AmgenGilead Sciences vs PfizerGilead Sciences vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 28.8B
Gross Profit 22.5B 78.26%
Operating Income 10.5B 36.53%
Net Income 480.0M 1.67%
EPS (Diluted) $0.38

Balance Sheet Metrics

Total Assets 59.0B
Total Liabilities 39.7B
Shareholders Equity 19.2B
Debt to Equity 2.07

Cash Flow Metrics

Operating Cash Flow 6.5B
Free Cash Flow 10.3B

Revenue & Profitability Trend

Gilead Sciences Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 28.8B 27.1B 27.3B 27.3B 24.7B
Cost of Goods Sold 6.3B 6.5B 5.7B 6.6B 4.6B
Gross Profit 22.5B 20.6B 21.6B 20.7B 20.1B
Operating Expenses 12.0B 11.8B 10.6B 9.8B 10.2B
Operating Income 10.5B 8.8B 11.0B 10.9B 9.9B
Pre-tax Income 690.0M 6.9B 5.8B 8.3B 1.7B
Income Tax 211.0M 1.2B 1.2B 2.1B 1.6B
Net Income 480.0M 5.6B 4.6B 6.2B 89.0M
EPS (Diluted) $0.38 $4.50 $3.64 $4.93 $0.10

Income Statement Trend

Gilead Sciences Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 19.2B 16.1B 14.4B 14.8B 16.0B
Non-Current Assets 39.8B 46.0B 48.7B 53.2B 52.4B
Total Assets 59.0B 62.1B 63.2B 68.0B 68.4B
Liabilities
Current Liabilities 12.0B 11.3B 11.2B 11.6B 11.4B
Non-Current Liabilities 27.7B 28.1B 30.7B 35.3B 38.8B
Total Liabilities 39.7B 39.4B 42.0B 46.9B 50.2B
Equity
Total Shareholders Equity 19.2B 22.7B 21.2B 21.1B 18.2B

Balance Sheet Composition

Gilead Sciences Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 480.0M 5.6B 4.6B 6.2B 89.0M
Operating Cash Flow 6.5B 7.3B 6.6B 10.1B 6.8B
Investing Activities
Capital Expenditures - - - - -
Investing Cash Flow -2.9B -1.7B -1.7B -2.6B -14.0B
Financing Activities
Dividends Paid -3.9B -3.8B -3.7B -3.6B -3.4B
Financing Cash Flow -3.4B -5.1B -6.5B -8.9B 770.0M
Free Cash Flow 10.3B 7.4B 8.3B 10.8B 7.5B

Cash Flow Trend

Gilead Sciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 22.31
Forward P/E 14.29
Price to Book 6.90
Price to Sales 4.60
PEG Ratio 14.29

Profitability Ratios

Profit Margin 20.76%
Operating Margin 38.49%
Return on Equity 32.65%
Return on Assets 12.14%

Financial Health

Current Ratio 1.37
Debt to Equity 130.79
Beta 0.31

Per Share Data

EPS (TTM) $4.76
Book Value per Share $15.39
Revenue per Share $23.05

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
gild 132.1B 22.31 6.90 32.65% 20.76% 130.79
Eli Lilly and 691.8B 62.76 46.33 77.28% 22.67% 243.61
Johnson & Johnson 364.1B 16.83 4.66 29.45% 24.42% 66.90
Merck & Co 198.5B 11.49 4.12 39.29% 27.27% 71.99
Amgen 146.5B 24.84 23.60 105.67% 17.39% 924.46
Pfizer 136.6B 17.41 1.51 8.62% 12.62% 68.84

Financial data is updated regularly. All figures are in the company's reporting currency.